Novo Nordisk Rebrands as 'Novo' in Strategic Move to Counter Eli Lilly's Growth
Novo Nordisk A/S (NYSE:NVO) is rebranding itself under a new identity, simply called “Novo,” and launching an internal cultural reset aimed at improving decision-making speed, commercial execution, and R&D aggressiveness. This move comes as the company faces increasing pressure from Eli Lilly in the obesity drug market. Novo remains the global leader with 59.6% branded-volume share but is losing ground to its rival’s rapid growth. The rebranding coincides with a Capital Markets Day on September 21, where new strategic ambitions will be unveiled. Despite strong financials—$309.1 billion in sales and $127.7 billion operating profit for 2025—the company spent DKK 8 billion on transformation efforts last year and saw its diabetes market share drop by nearly four percentage points. If successful, the cultural shift could help Novo better leverage its obesity portfolio and next-gen treatments ahead of a patent cliff in semaglutide. However, risks remain: Lilly’s Mounjaro and Zepbound are outpacing Wegovy sales, with recent results showing significant revenue growth for Eli Lilly.
Topics: Company Restructuring Market Competition Obesity Drugs Pharmaceuticals